Abstract
Vancomycin-intermediate Staphylococcus aureus (VISA) strains have been reported in many countries around the world and their prevalence is increasing. The incidence of these strains in Iran has been reported in some studies, however there is no overall estimation of the VISA incidence in Iran. The objective of this systematic review was to estimate the total prevalence of VISA strains reported from Iran. A systematic literature review of relevant articles published on 'S. aureus isolates with intermediate resistance to vancomycin in Iran' was performed in PubMed and Scopus databases in the period 2010-2017. From 335 records found in the electronic search, 40 related studies were included in the current analysis. This systematic review indicated that the overall prevalence rate of VISA was 0.09% [95% confidence interval (CI) 0.00-0.20] in Iran in 2010-2017. In the classification of VISA based on location, the highest frequency was in Mazandaran Province at 8.36% (95% CI 0.00-18.49%). The most prevalent VISA genotypes in Iran were staphylococcal cassette chromosome mec (SCCmec) type III, accessory gene regulator (agr) group II, sequence type 22 (ST22) and staphylococcal protein A (spa) type t790. Regarding the upward trend in the incidence of VISA strains in Iran and the importance of preventing VISA in public health, it is recommended to control nosocomial infections and to be cautious in the use of vancomycin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
